Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study to collect information on the safety, especially serious infections and malignancies, and efficacy of the long-term use of ORENCIA Intravenous Infusion 250mg in patients with rheumatoid arthritis.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Ono Pharmaceutical Co. Ltd
• Treatments: Abatacept

Criteria

Inclusion Criteria:

• Patients who are beginning to receive the treatment with ORENCIA Intravenous Infusion 250mg under the approved indications, dosage, and administration

• Have available HAQ data

• Have available DAS28-ESR or DAS28- CRP data

• Have no past or present history of malignancies

• Are expected to be followed up for 3 years